Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1836.

https://doi.org/10.1182/blood-2019-124484

Published: 2019

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

Journal Articles

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Cyrille Hulin, MD, Margaret Macro, MD, Sophie Gourgou, Bertrand Arnulf, MD PhD, Florence Lachenal, Caroline Lenoir, Anne-Marie Stoppa, MD, Marie Lorraine Chretien, Laure Vincent, Aurore Perrot, MD, Philippe Moreau, MDPhD, Lionel Karlin, MD, Cécile Fohrer, Jean-Richard Eveilard, Jean Fontan, MD, Olivier Decaux

Blood (2017) 130 (Supplement 1): 1848.

https://doi.org/10.1182/blood.V130.Suppl_1.1848.1848

Published: 2017

Journal Articles

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Murielle Roussel, MD, Valerie Lauwers-Cances, MD, Nelly Robillard, PhD, Karim Belhadj, MD, Thierry Facon, MD PhD, Laurent Garderet, MD, Martine Escoffre, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MD PhD, Denis Caillot, Cecile Fohrer, MD, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, MD PhD, Michel Attal

Blood (2016) 128 (22): 1142.

https://doi.org/10.1182/blood.V128.22.1142.1142

Published: 2016

Journal Articles

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Eileen Mary Boyle, MD MSc, Marie-Odile Petillon, MD, Charles Herbaux, MD, Johanna Mimouni, Xavier Leleu, Lionel Karlin, MD, Chantal Doyen, MD, Marc Wetterwald, MD PhD, Muriel Roussel, MD, Cyrille Hulin, Bruno Royer, MD, Margaret Macro, Philippe Moreau, Karel Fostier, MD, Mamoun Dib, Sabine Brechignac, MD, Caroline Bureau, Gerald Marit, MD, Adrian Tempescul, MD, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, MD, Aurore Perrot, MD, Lotfi Benboubker, MD PhD, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, MD PhD, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, MD, Laurent Frenzel, Bertrand Arnulf, MD, Mohamad Mohty, MD PhD, Philippe Rodon, MD, Brigitte Kolb, Olivier Decaux, MD PhD, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, MD, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, MD PhD, Michel Attal, Susanna Schraen, PharmD, Thierry Facon

Blood (2016) 128 (22): 2138.

https://doi.org/10.1182/blood.V128.22.2138.2138

Published: 2016

Journal Articles

Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Stéphanie Guidez, Guillemette Fouquet, Hélène Demarquette, Morgane Nudel, Eileen Boyle, Marie Lorraine Chretien, Denis Caillot, Lionel Karlin, Cyrille Hulin, Olivier Decaux, MD PhD, Bertrand Arnulf, Cécile Fohrer, Margaret MACRO, MD, Charles Lancesseur, Murielle Roussel, Benjamin Hebraud, Thierry Facon, Xavier Leleu, MD PhD

Blood (2015) 126 (23): 5379.

https://doi.org/10.1182/blood.V126.23.5379.5379

Published: 2015

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Blood (2012) 120 (21): 933.

https://doi.org/10.1182/blood.V120.21.933.933

Published: 2012

Journal Articles

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Patrice Chevallier, Nelly Robillard, Aude Charbonnier, Emmanuel Raffoux, Sebastien Maury, Sylvain Carras, Cecile Chabrot, Cecile Fohrer, Marc Bernard, Jean-Sebastien Blade, Anne Etienne, Pascaline Talmant, Jacques Delaunay, Thierry Guillaume, Mohamad Mohty, Marie-Christine Bene, Norbert Ifrah, Herve Dombret

Blood (2012) 119 (11): 2474–2477.

https://doi.org/10.1182/blood-2011-11-390781

Published: 2012

Journal Articles

Trastuzumab (Herceptin®) for Treatment of Refractory/Relapsed HER2 Positive Adult B-ALL: Results of a Phase II GRAALL Study

Patrice Chevallier, MD, Nelly Robillard, Aude Charbonnier, Emmanuel Raffoux, MD, PhD, Sébastien Maury, Sylvain Carras, Cecile Chabrot, Cecile Fohrer, Marc Bernard, Jean-Sebastien Blade, Anne Etienne, MD, Pascaline Talmant, Jacques Delaunay, Thierry Guillaume, Mohamad Mohty, Norbert Ifrah, Herve Dombret

Blood (2011) 118 (21): 1525.

https://doi.org/10.1182/blood.V118.21.1525.1525

Published: 2011

Journal Articles

Successful Treatment af a Hairy Cell Leukemia (HCL) with Pentostatin in a Cardiac Transplant Recipient.

Alina Zamfir, MD, Vincent Leymarie, MD, Anne-Cecile Galoisy, MD, Annie Falkenrodt, MD, Eric Epailly, MD, Cecile Fohrer, MD, Lahoucine Mahmal, MD, Raoul Herbrecht, MD

Blood (2004) 104 (11): 4815.

https://doi.org/10.1182/blood.V104.11.4815.4815

Published: 2004

Journal Articles

Management of Acute Myeloid Leukemia (AML) in First Relapse: Retrospective Analysis about 101 Adults Cases Receiving Homogeneous First-Line Therapy. Impact of Prognostic Factors and Treatment.

Cecile Fohrer, Brigitte Witz, Jean Luc Harousseau, Francis Witz, Shanti Ame, Frederic Maloisel, Karin Bilger, Raoul Herbrecht, Bruno Lioure

Blood (2004) 104 (11): 882.

https://doi.org/10.1182/blood.V104.11.882.882

Published: 2004

NARROW

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Trastuzumab (Herceptin®) for Treatment of Refractory/Relapsed HER2 Positive Adult B-ALL: Results of a Phase II GRAALL Study

Successful Treatment af a Hairy Cell Leukemia (HCL) with Pentostatin in a Cardiac Transplant Recipient.

Management of Acute Myeloid Leukemia (AML) in First Relapse: Retrospective Analysis about 101 Adults Cases Receiving Homogeneous First-Line Therapy. Impact of Prognostic Factors and Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only